Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Phase 3

Terminated

Conditions: Allergy, Peanut

Interventions: Drug: ligelizumab
Drug: Placebo

First Posted Date: 2021-08-02

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 211

Registration Number: NCT04984876

Locations: 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸
Allergy and Immunology Associates, Scottsdale, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 27 locations

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

Phase 2

Active, not recruiting

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)

Interventions: Drug: Alpelisib

First Posted Date: 2021-07-28

Last Posted Date: 2024-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT04980833

Locations: 🇺🇸
Boston Childrens Hospital ., Boston, Massachusetts, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3

Active, not recruiting

Conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Interventions: Drug: Imatinib
Drug: Asciminib
Drug: Nilotinib
Drug: Bosutinib
Drug: Dasatinib

First Posted Date: 2021-07-21

Last Posted Date: 2024-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 404

Registration Number: NCT04971226

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸
Texas Oncology Austin, Dallas, Texas, United States
🇺🇸
Texas Oncology Texas Onc - Amarillo, Dallas, Texas, United States

and more 12 locations

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Recruiting

Conditions: Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation

Interventions: Other: Alpelisib
Other: Fulvestrant

First Posted Date: 2021-07-19

Last Posted Date: 2023-09-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT04967248

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Recruiting

Conditions: Melanoma

Interventions: Drug: dabrafenib
Drug: trametinib

First Posted Date: 2021-07-14

Last Posted Date: 2024-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT04961619

Locations: 🇹🇷
Novartis Investigative Site, Kecioren Ankara, Turkey

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: NIS793
Drug: Bevacizumab
Drug: Modified FOLFOX6
Drug: FOLFIRI
Drug: Tislelizumab

First Posted Date: 2021-07-07

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 204

Registration Number: NCT04952753

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
University of Michigan Medical, Ann Arbor, Michigan, United States
🇺🇸
WA Uni School Of Med, Saint Louis, Missouri, United States

and more 5 locations

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Phase 3

Active, not recruiting

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: ABL001 40mg BID
Drug: ABL001 80mg QD
Drug: ABL001 200mg QD

First Posted Date: 2021-07-01

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 199

Registration Number: NCT04948333

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: CSJ117
Drug: Placebo

First Posted Date: 2021-06-30

Last Posted Date: 2022-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 136

Registration Number: NCT04946318

Locations: 🇸🇰
Novartis Investigative Site, Levice, Slovakia

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Completed

Conditions: Somatostatin Receptor-positive GEP-NET

Interventions: Other: Lutathera

First Posted Date: 2021-06-30

Last Posted Date: 2024-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT04946305

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

Recruiting

Conditions: Breast Cancer

Interventions: Other: ribociclib
Other: mono endocrine therapy
Other: aplelicib
Other: chemotherapy

First Posted Date: 2021-06-29

Last Posted Date: 2024-02-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3290

Registration Number: NCT04943497

Locations: 🇷🇺
Novartis Investigative Site, Voronezh, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy